A new acidic microenvironment related lncRNA signature predicts the prognosis of liver cancer patients

Univariate Gene signature
DOI: 10.3389/fonc.2022.1016721 Publication Date: 2022-10-31T07:12:49Z
ABSTRACT
The acidic microenvironment (AME), like hypoxia, inflammation, or immunoreaction, is a hallmark of the tumor (TME). This work aimed to develop prediction signature dependent on AME-associated lncRNAs in order predict prognosis LC individuals.We downloaded RNA-seq information and corresponding clinical predictive data from Cancer Genome Atlas (TCGA) dataset conducted univariate multivariate Cox regression analyses identify for construction Kaplan-Meier technique was utilized determine overall survival (OS) rate high (H)-risk low (L)-risk groups. Using gene set enrichment analysis (GSEA) functional variations between H- L-risk groups were investigated. association immunological state investigated using single-sample GSEA (ssGSEA). Additionally, predicted therapeutic response individuals evaluated. Lastly, quantitative reverse transcription polymerase chain reaction (qRT-PCR) performed verify risk model.We generated comprised seven (LINC01116, AC002511.2, LINC00426, ARHGAP31-AS1, LINC01060, TMCC1-AS1, AC012065.1). H-risk group had worse than L- group. lncRNA might with independently. AME-related shows greater effectiveness clinic-pathological factors, an area under receiver operating characteristic (ROC) curve 0.806%. When participants categorized based several clinico-pathological characteristics, OS high-risk shorter compared low-risk patients. demonstrated that metabolism different acids PPAR signaling pathway are closely associated individuals. prognostic substantially status individuals, as determined by ssGSEA. High more sensitive some immunotherapies (including anti-TNFSF4 anti-SIRPA, anti-CD276 anti-TNFSF15) conventional chemotherapy drugs lapatinib paclitaxel). Finally, expression levels comprising tested qRT-PCR.A basis mechanism provided signature, which also offers recommendations
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (22)